NCT02437045View on ClinicalTrials.gov

Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Bloodstream Infections
Interventions
DRUG

Meropenem

Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.

DRUG

Piperacillin-tazobactam combination product

Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.

Trial Locations (6)

2305

John Hunter Hospital, New Lambton

4101

Princess Alexandra Hospital, Brisbane

4170

Royal Brisbane Hospital, Brisbane

Unknown

Wollongong Hospital, Wollongong

National University Hospital Singapore, Singapore

Tan Tock Seng Hospital, Singapore

All Listed Sponsors
lead

The University of Queensland

OTHER

NCT02437045 - Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response | Biotech Hunter | Biotech Hunter